Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.

Search our Collections & Repository

All these words:

For very narrow results

This exact word or phrase:

When looking for a specific result

Any of these words:

Best used for discovery & interchangable words

None of these words:

Recommended to be used in conjunction with other fields

Language:

Dates

Publication Date Range:

to

Document Data

Title:

Document Type:

Library

Collection:

Series:

People

Author:

Help
Clear All

Query Builder

Query box

Help
Clear All

For additional assistance using the Custom Query please check out our Help Page

i

Superseded


This Document Has Been Replaced By: Prevention and control of seasonal influenza with vaccines : recommendations of the Advisory Committee on Immunization Practices — United States, 2017–18 influenza season

Notice to Readers: Expansion of Use of Live Attenuated Influenza Vaccine (FluMist ) to Children Aged 2--4 Years and Other FluMist Changes for the 2007--08 Influenza Season. MMWR 2007. 56 (46): 1217-1219.

  • November 23, 2007

Filetype[HTM]


Select to view the document on External site.
This document file type cannot be previewed
  • English
    • Details You May Also Like

    Details:

    • Description:
      On September 19, 2007, MedImmune Vaccines (Gaithersburg, Maryland) received approval from the Food and Drug Administration (FDA) to expand the use of FluMist , a live, attenuated influenza vaccine (LAIV), to children aged 2--4 years (i.e., 24--49 months). FluMist is an intranasally administered influenza vaccine that was first licensed by the FDA in 2003 for healthy, nonpregnant persons aged 5--49 years (1). Expanding the age indications to include healthy children aged 2--4 years provides another influenza vaccination option for young children. In granting the new approval, FDA emphasized that FluMist is not approved for vaccination of children aged <2 years or adults aged >49 years, and that FluMist safety has not been established in persons with underlying medical conditions predisposing them to influenza-related complications (2). In addition, FluMist should not be administered to persons with asthma or children aged <5 years with recurrent wheezing (1,2).
    • Document Type:
      Journal Article
    • Collection(s):
    • Main Document Checksum:
    • File Type:

    Supporting Files

    • No Additional Files

    More +

    You May Also Like

    Checkout today's featured content at stacks.cdc.gov